The present application relates to probiotic compositions, e.g., comprising at least one bacterial strain selected from: Streptococcus thermophiles, Bifidobacterium longum, Bifidobacterium breve, Bifidobacterium infantis, Lactobacillus acidophilus, Lactobacillus plantarum, Lactobacillus paracasei, KE99, and Lactobacillus bulgaricus, optionally wherein the at least one bacterial strain is either alive or sonicated.

The present application relates to probiotic compositions, e.g., comprising at least one bacterial strain selected from: Streptococcus thermophiles, Bifidobacterium longum, Bifidobacterium breve, Bifidobacterium infantis, Lactobacillus acidophilus, Lactobacillus plantarum, Lactobacillus paracasei, KE99, and Lactobacillus bulgaricus, optionally wherein the at least one bacterial strain is either alive or sonicated.

The present invention relates to anti-cancer agents comprising 1,2,4-trioxane compounds and anti-cancer agents comprising combinations comprising 1,2,4-trioxane compounds and chlorogenic acids. The invention further provides pharmaceutical compositions comprising such anti-cancer agents, kits comprising the same as well as methods and treatment regimens of using the aforementioned anti-cancer agents, pharmaceutical compositions and kits in the treatment and prevention of cancer and for prolonging survival of subjects having cancer, in particular ovarian cancer or lung cancer.

The present invention relates to anti-cancer agents comprising 1,2,4-trioxane compounds and anti-cancer agents comprising combinations comprising 1,2,4-trioxane compounds and chlorogenic acids. The invention further provides pharmaceutical compositions comprising such anti-cancer agents, kits comprising the same as well as methods and treatment regimens of using the aforementioned anti-cancer agents, pharmaceutical compositions and kits in the treatment and prevention of cancer and for prolonging survival of subjects having cancer, in particular ovarian cancer or lung cancer.

The present invention relates to anti-cancer agents comprising 1,2,4-trioxane compounds and anti-cancer agents comprising combinations comprising 1,2,4-trioxane compounds and chlorogenic acids. The invention further provides pharmaceutical compositions comprising such anti-cancer agents, kits comprising the same as well as methods and treatment regimens of using the aforementioned anti-cancer agents, pharmaceutical compositions and kits in the treatment and prevention of cancer and for prolonging survival of subjects having cancer, in particular ovarian cancer or lung cancer.

Provided are implantable and biodegradable drug delivery devices capable of delivering an active pharmaceutical ingredient (API) directly to a target tissue site. The drug delivery devices can include at least two layers. One of the layers can include the API and a biodegradable polymer and a second layer can include another biodegradable polymer that degrades slower than the first biodegradable polymer. When the device is placed directly on the target tissue, the API layer can degrade thereby releasing the API towards the target tissue while the non-API layer can prevent the API from being released away from the target tissue onto non-target tissue.

Provided are implantable and biodegradable drug delivery devices capable of delivering an active pharmaceutical ingredient (API) directly to a target tissue site. The drug delivery devices can include at least two layers. One of the layers can include the API and a biodegradable polymer and a second layer can include another biodegradable polymer that degrades slower than the first biodegradable polymer. When the device is placed directly on the target tissue, the API layer can degrade thereby releasing the API towards the target tissue while the non-API layer can prevent the API from being released away from the target tissue onto non-target tissue.

System for inducing sonoporation of a drug into cancer cells in a tumor and method thereof, the system comprising a generator configured to provide electrical energy at an ultrasound frequency; an ultrasound probe electrically connected to the generator and configured to convert the electrical energy into low intensity pulsed ultrasonic waves defined by operation parameters, said operation parameters comprising the frequency, the duty cycle, the operation time of the ultrasonic waves; an input device enabling an operator to enter configuration data comprising: type of tumor, type of drug, localization of secondary tumor, anthropometric measurements and grade of tumor, and a processor configured to determine the values of the operation parameters on the basis of the entered configuration data and control the generator and the ultrasound probe to operate according to said determined values, wherein the value of the frequency is determined on the basis of the type of tumor, the localization of the tumor, the grade of tumor and the anthropometric measurements, the value of the duty cycle is determined on the basis of the drug, the type of tumor and the grade of the tumor, and the value of said operation time being determined on the basis of at least the type of tumor and the type of drug.

System for inducing sonoporation of a drug into cancer cells in a tumor and method thereof, the system comprising a generator configured to provide electrical energy at an ultrasound frequency; an ultrasound probe electrically connected to the generator and configured to convert the electrical energy into low intensity pulsed ultrasonic waves defined by operation parameters, said operation parameters comprising the frequency, the duty cycle, the operation time of the ultrasonic waves; an input device enabling an operator to enter configuration data comprising: type of tumor, type of drug, localization of secondary tumor, anthropometric measurements and grade of tumor, and a processor configured to determine the values of the operation parameters on the basis of the entered configuration data and control the generator and the ultrasound probe to operate according to said determined values, wherein the value of the frequency is determined on the basis of the type of tumor, the localization of the tumor, the grade of tumor and the anthropometric measurements, the value of the duty cycle is determined on the basis of the drug, the type of tumor and the grade of the tumor, and the value of said operation time being determined on the basis of at least the type of tumor and the type of drug.

Combination therapies including a Apurinic/Apyrimidinic Endonuclease/reduction-oxidation (redox) Factor-1 (APE1/Ref-1) inhibitor specific to inhibit the redox function of APE1/Ref-1 are disclosed herein. The Combination therapies can be used for treating various cancers, as well as other angiogenesis-mediated diseases (e.g., retinal diseases, cardiovascular diseases).